On Tuesday, the SEC filed civil complaints against two brothers accused of buying stock based on secret knowledge of the then-upcoming takeover--the 8th case the Commission has brought against insider trading connected to that deal, it says.
The Securities and Exchange Commission's insider trading team has Dendreon under a microscope. The agency has launched a civil investigation into stock trades by former CEO Mitchell Gold to see whether he acted on inside information about disappointing Provenge sales.
Severe hypersensitivity reactions in Omontys patients prompted Affymax and Takeda Pharmaceutical to recall all lots of the anemia drug, designed for use in dialysis patients.
Novartis may be looking at another trial of its troubled blood pressure drug Tekturna. This would not be a clinical trial, however, but more of the civil or criminal kind.
On the eve of Forest Laboratories' proxy vote, activist investor Carl Icahn is still campaigning. After accusing Forest's board of cronyism and lethargy, after critiquing CEO Howard Solomon's performance--and his son's résumé--Icahn is taking the company to task for a recent FDA warning letter.
Was something rotten in Stiefel Laboratories ' dealings with employee-shareholders before its sale to GlaxoSmithKline ($GSK)? The Securities and Exchange Commission believes so. The U.S. agency
When he sold his company Stiefel Laboratories to GlaxoSmithKline ($GSK) in 2009, Charles Stiefel appeared to be a lucky man. But now, roughly two years later, the Securities and Exchange Commission
In an unusual twist to a boardroom spat at Elan, the Irish drugmaker has reported one of its own directors to the U.S. Securities and Exchange Commission for potential insider-trading allegations.
Merck (NYSE: MRK) has been roped into a federal probe of pharma's foreign operations. The Justice Department and Securities and Exchange Commission are investigating the drugmaker for Foreign Corrupt
Did Mylan divulge confidential information to some selected investors last fall? The Securities and Exchange Commission wants to know. The regulator has asked several investment banks about a